Nanobiotix secures €9m funding from bpifrance to advance NBTXR3 development
Granted through bpifrance’s Strategic Industrial Innovation (ISI) program, the funding is to expedite the clinical and industrial development of NBTXR3 in a new indication, liver cancer. Liver cancer